Dr. Gautham Nadig, Ph.D.

Co-founder and Executive Director

Gautham Nadig is co-founder and Executive Director of Mynvax Private Limited. Prior to co-founding Mynvax, Dr. Nadig was co-founder and Executive Director of Metahelix Life Sciences, a successful agri-biotech Company ...focused on molecular breeding, crop improvement and transgenic technologies. Metahelix was acquired by Rallis, a TATA group Company in 2016 and is currently amongst the fastest growing seed businesses in India. An alumnus of Bangalore University (M.Sc., Physics) and Indian Institute of Science ( Ph.D., Molecular Biophysics), Dr. Nadig worked at the Monsanto Research Centre, India after a brief post-doctoral stint at the Department of Chemistry, Pennsylvania State University, USA.

Read more

Dr. Raghavan Varadarajan, Ph.D.

Co-founder and Non-Executive Director

Dr. Varadarajan is co-founder and non-executive director of Mynvax. He is currently a Professor at the Molecular Biophysics Unit, Indian Institute of Science, where he leads an active research group. ... He is well known for his basic research in the fields of protein structure, stability and folding and its applications towards developing vaccines against influenza, HIV-1 and SARS-Cov-2. He is the recipient of numerous awards including the Shanti Swarup Bhatnagar Prize for Science and Technology for his contributions to biological sciences in 2002 [5], the G. N. Ramachandran Gold Medal for Excellence in Biological Sciences and Technology in 2013. and The World Academy of Sciences Award in Biology in 2024. His work has been funded by numerous national (DBT, DST, ICMR, CSIR) and international (Wellcome Trust, NIH, IAVI, and the Gates Foundation) agencies. He is an elected fellow of the Indian National Science Academy and the Indian Academy of Sciences, serving multiple stints on the Council of the latter, including as Vice-President. He also served as the President of the Indian Biophysical Society. Raghavan received his MSc degree in Chemistry from IIT Kanpur in 1982 followed by a Ph.D. from Stanford and a postdoctoral stint at Yale University, returning to IISc to take up a Faculty position in 1992.

Read more

Dr. Ganesh M. Kishore, Ph.D.

Non-Executive Director

Dr. Kishore is a non-executive director of Mynvax and joined the Board of the Company in December 2017. He is currently co-founder and Managing Partner at Spruce Capital Partners. He has a distinguished track record of ... accomplishments in biotechnology research and development, and business. After receiving a Ph.D. in biochemistry from the Indian Institute of Science, Dr. Kishore received postdoctoral training in chemistry and biology at the University of Texas at Austin.

He then joined Monsanto, where he made contributions to the discovery of Roundup Ready technology and the synthesis of Aspartame. During his tenure at Monsanto, he was named a Distinguished Science Fellow, and won the prestigious Queeny Award. Before moving to DuPont, he served as the President of Monsanto’s Nutrition & Consumer Sector. He joined DuPont as the Chief Technology Officer of Agriculture & Nutrition. He retired from DuPont as Chief Biotechnology Officer to join Malaysian Life Science Capital Fund and later co-founded Spruce Capital Partners.

Dr. Kishore currently serves on the Spruce portfolio company boards of Amfora, Consumer Physics, GreenLight Biosciences and Provivi. He is a recipient of BIO’s Legacy Award and the American Society of Plant Biologists Innovation Award.

Read more

Arun S. Chandavarkar, Ph.D.

Non-Executive Director

Arun Chandavarkar, Ph.D. was until recently, Managing Director of Biocon Biologics Limited, a subsidiary of Biocon Ltd., and has been a member of the board of Mynvax ... since January 2021 when he was appointed as an Independent Director. He was CEO and Joint Managing Director of Biocon Ltd. from April 2014 to November 2019 when he retired after a nearly three-decade-long career at Biocon. Prior to becoming CEO, he held the position of Chief Operating Officer at Biocon.

Dr Chandavarkar was a part of the core team that led Biocon’s growth and strategy focused on improving access to high quality, affordable biopharmaceuticals and specialty medicines in chronic therapies such as diabetes, oncology and immunology. Under his leadership, Biocon made significant investments in cutting-edge R&D and efficient, compliant operations that translated into a unique and differentiated product portfolio straddling fermentation-derived complex generics, biosimilars and novel biologics, all aimed at a worldwide patient population. Dr Chandavarkar graduated in Chemical Engineering from the Indian Institute of Technology (IIT), Mumbai and holds a Ph.D. in Biochemical Engineering from MIT, Cambridge, U.S.A.

He served as Chairperson of the National Committee on Biotechnology of the Confederation of Indian Industry (CII) for the year 2016-17.

Read more

Mr. Anil Gudibande

Non-Executive Director

Anil Gudibande is a non-executive Director and nominee director of 1Crowd, and amongst the first investors in Mynvax from the seed stage of the Company. Anil has ... over 27 years of experience in Banking. He spent 17 years with Citigroup and was most recently with Royal Bank of Scotland - initially as Managing Director & Co-Head of the Investment Bank, and subsequently as Managing Director with the International Banking division, where he led a team of bankers covering some of the largest corporate clients. He also spent a year with AIG Private Equity.

Anil has worked on a number of marquee deals in M&A, acquisition financing, IPOs, loan and bond issuances. He was also a senior business approver with credit approval authority. Anil is an angel investor who mentors a few start-ups. He is a member of the Institute of Chartered Accountants of India, and the Institute of Cost & Works Accountants of India. He holds a Master’s degree in Commerce from Bangalore University.

Read more

Mr. Mahendran Balachandran

Non-Executive Director

Mahendran Balachandran is non-Executive and nominee director of Accel on the Board of Mynvax. Mahendran joined the Board of Mynvax in August 2022 ... after Accel led a Series A investment into the Company. He has been venture investing since 2005 bringing with him two decades of business leadership in technology companies, including Apple and Tektronix. As a partner at Accel, he is responsible for investments in Bayestree, Indifi, Finbots, Probe, Power2SME, Sayre, Samunnati, USPL, Vinculum, and Zumutor. Mahendran holds a management degree from IIM Bangalore and a B.Tech degree from NITW.

Read more